NanoDx ™ Announces Collaboration with the Home Base Program
Focused on identification and management of the long-term issues associated with Traumatic Brain Injury in both active and retired military personnel.
Boston, MA – June 15, 2021 – NanoDx, Inc., a privately held medical device company developing cutting-edge and rapid, point-of-care diagnostic products for the objective diagnosis and management of Traumatic Brain Injury (TBI), today announced that it has formed a partnership with the Home Base Program to increase the awareness of the long-term issues associated with TBI in both active and retired military personnel.
“Early detection of TBI is critical in minimizing the long-term effects of injuries sustained in training or deployment,” stated James Wylie, Executive Chairman of NanoDx. “Our handheld NanoDx™ System was designed for rapid, point-of-injury diagnosis and is capable of delivering a direct test result in less than 2 minutes from a drop of whole blood.”
Home Base, a Red Sox Foundation and Massachusetts General Hospital Program, is dedicated to healing the invisible wounds of war through world-class clinical care, wellness, education, and research. As a National Center of Excellence, Home Base operates the first and largest private-sector clinic in the nation devoted to providing life-saving clinical care and support for the treatment of post-traumatic stress, traumatic brain injury, anxiety, depression, and other issues associated with military service.
Michael Allard, Chief Operating Officer of Home Base commented, “Home Base believes that early detection of TBI is critical to its Mission. Our newly formed collaboration with NanoDx will focus on developing educational programs and special events, public relations and communications, and seeking funding grants to support our mutual goals.”
About NanoDx, Inc.
NanoDx, Inc., is a privately held medical device company developing breakthrough, point-of-care diagnostic solutions that address unmet market needs and improve patient outcomes while reducing healthcare costs. The company's flagship product, the NanoDx™ System, is capable of detecting and quantifying biomarkers (analytes) from a small fluid specimen in less than 2 minutes. NanoDx's platform utilizes a proprietary nanosensor technology with a broad range of potential diagnostic applications including COVID-19, Traumatic Brain Injury (TBI), Influenza, Sepsis and Stroke. www.NanoDiagnostics.com